Serum tartrate-resistant acid phosphatase 5b (TRACP5b) activity as a biomarker for bone metastasis in non-small cell lung cancer patients

Clinica Chimica Acta

Volumn 412, Issue 1-2, 2011, Pages 181-185

  Yao, Nai Shun ^a   Wu, Yi Ying ^a   Janckila, Anthony J ^b   Ku, Chih Hung ^c   Hsieh, An Tai ^a   Ho, Ching Liang ^a   Lee, Su Huei ^a   Chao, Tsu Yi ^a,d,e  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b Division of Hematology   (United States)

^c NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Bone metastasis; Lung cancer; Osteoclast; Tartrate resistant acid phosphatase 5b

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME 5B; BIOLOGICAL MARKER; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER LOCALIZATION; CANCER SCREENING; CANCER STAGING; CONTROLLED STUDY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; OSTEOCLAST; PH MEASUREMENT; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE;

ACID PHOSPHATASE; ADULT; AGED; AGED, 80 AND OVER; BONE NEOPLASMS; CARCINOMA, NON-SMALL-CELL LUNG; CASE-CONTROL STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; ISOENZYMES; LUNG NEOPLASMS; MALE; MIDDLE AGED; ROC CURVE; TUMOR MARKERS, BIOLOGICAL;

EID: 78650512206     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2010.09.038     Document Type: Article

References (31)

1. Bach F., Larsen B.H., Rohde K., et al. Metastatic spinal cord compression. Occurrence, symptoms, clinical presentations and prognosis in 398 patients with spinal cord compression. Acta Neurochir (Wien) 1990, 107:37-43.
2. Napoli L.D., Hansen H.H., Muggia F.M., Twigg H.L. The incidence of osseous involvement in lung cancer, with special reference to the development of osteoblastic changes. Radiology 1973, 108:17-21.
3. Fulfaro F., Casuccio A., Ticozzi C., Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: a review of phase III trials. Pain 1998, 78:157-169.
4. Theriault R.L., Lipton A., Hortobagyi G.N., et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999, 17:846-854.
5. Coleman R.E. Uses and abuses of bisphosphonates. Ann Oncol 2000, 11(Suppl 3):179-184.
6. Hortobagyi G.N., Theriault R.L., Porter L., et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996, 335:1785-1791.
7. Vinholes J., Coleman R., Eastell R. Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment. Cancer Treat Rev 1996, 22:289-331.
8. Ebert W., Muley T., Herb K.P., Schmidt-Gayk H. Comparison of bone scintigraphy with bone markers in the diagnosis of bone metastasis in lung carcinoma patients. Anticancer Res 2004, 24:3193-3201.
9. Hillner B.E., Ingle J.N., Berenson J.R., et al. American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel.[comment]. J Clini Oncol 2000, 18:1378-1391.
10. Lipton A., Costa L., Ali S., Demers L. Use of markers of bone turnover for monitoring bone metastases and the response to therapy. Semin Oncol 2001, 28:54-59.
11. Minkin C. Bone acid phosphatase: tartrate-resistant acid phosphatase as a marker of osteoclast function. Calcif Tissue Int 1982, 34:285-290.
12. Janckila A.J., Takahashi K., Sun S.Z., Yam L.T. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 2001, 47:74-80.
13. Hannon R., Blumsohn A., Naylor K., Eastell R. Response of biochemical markers of bone turnover to hormone replacement therapy: impact of biological variability. J Bone Miner Res 1998, 13:1124-1133.
14. Halleen J.M., Alatalo S.L., Janckila A.J., Woitge H.W., Seibel M.J., Vaananen H.K. Serum tartrate-resistant acid phosphatase 5b is a specific and sensitive marker of bone resorption. Clin Chem 2001, 47:597-600.
15. Wada N., Ishii S., Ikeda T., Enomoto K., Kitajima M. Serum tartrate resistant acid phosphatase as a potential marker of bone metastasis from breast cancer. Anticancer Res 1999, 19:4515-4521.
16. Chao T.Y., Ho C.L., Lee S.H., Chen M.M., Janckila A., Yam L.T. Tartrate-resistant acid phosphatase 5b as a serum marker of bone metastasis in breast cancer patients. J Biomed Sci 2004, 11:511-516.
17. Chao T.Y., Yu J.C., Ku C.H., et al. Tartrate-resistant acid phosphatase 5b is a useful serum marker for extensive bone metastasis in breast cancer patients. Clin Cancer Res 2005, 11:544-550.
18. Chung Y.C., Ku C.H., Chao T.Y., Yu J.C., Chen M.M., Lee S.H. Tartrate-resistant acid phosphatase 5b activity is a useful bone marker for monitoring bone metastases in breast cancer patients after treatment. Cancer Epidemiol Biomark Prev 2006, 15:424-428.
19. Tsai S.H., Chen C.Y., Ku C.H., et al. The semiquantitative bone scintigraphy index correlates with serum tartrate-resistant acid phosphatase activity in breast cancer patients with bone metastasis. Mayo Clin Proc 2007, 82:917-926.
20. Terpos E., Kiagia M., Karapanagiotou E.M., et al. The clinical significance of serum markers of bone turnover in NSCLC patients: surveillance, management and prognostic implications. Anticancer Res 2009, 29:1651-1657.
21. Koizumi M., Takahashi S., Ogata E. Comparison of serum bone resorption markers in the diagnosis of skeletal metastasis. Anticancer Res 2003, 23:4095-4099.
22. Halleen J.M., Alatalo S.L., Suominen H., Cheng S., Janckila A.J., Vaananen H.K. Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption. J Bone Miner Res 2000, 15:1337-1345.
23. Janckila A.J., Takahashi K., Sun S.Z., Yam L.T. Tartrate-resistant acid phosphatase isoform 5b as serum marker for osteoclastic activity. Clin Chem 2001, 47:74-80.
24. Takahashi K., Janckila A.J., Sun S.Z., Lederer E.D., Ray P.C., Yam L.T. Electrophoretic study of tartrate-resistant acid phosphatase isoforms in endstage renal disease and rheumatoid arthritis. Clin Chim Acta 2000, 301:147-158.
25. Nakanishi M., Yoh K., Miura T., Ohasi T., Rai S.K., Uchida K. Development of a kinetic assay for band 5b tartrate-resistant acid phosphatase activity in serum. Clin Chem 2000, 46:469-473.
26. Weiss W., Gillick J.S. The metastatic spread of bronchogenic carcinoma in relation to the interval between resection and death. Chest 1977, 71:725-729.
27. Roodman G.D. Mechanisms of bone metastasis. N Engl J Med 2004, 350:1655-1664.
28. Hayman A.R., Macary P., Lehner P.J., Cox T.M. Tartrate-resistant acid phosphatase (Acp 5): identification in diverse human tissues and dendritic cells. J Histochem Cytochem 2001, 49:675-684.
29. Yaziji H., Janckila A.J., Lear S.C., Martin A.W., Yam L.T. Immunohistochemical detection of tartrate-resistant acid phosphatase in non-hematopoietic human tissues. Am J Clin Pathol 1995, 104:397-402.
30. Karapanagiotou E.M., Terpos E., Dilana K.D., et al. Serum bone turnover markers may be involved in the metastatic potential of lung cancer patients. Med Oncol 2010, 27(2):332-338.
31. Capeller B., Caffier H., Sutterlin M.W., Dietl J. Evaluation of tartrate-resistant acid phosphatase (TRAP) 5b as serum marker of bone metastases in human breast cancer. Anticancer Res 2003, 23:1011-1015.